InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $1.270 0.01 (0.79%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$39 Appendix 4E - Preliminary Final Report 30 June 2017 24 Aug 2017 4:47PM $0.091 $1.270 risen by 1,295.60%
$39 First UK subject recruited 22 Aug 2017 9:27AM $0.089 $1.270 risen by 1,326.97%
$39 CE Mark & Quarterly Activity Update 31 Jul 2017 9:32AM $0.102 $1.270 risen by 1,145.10%
$39 Resignation of Company Secretary 25 Jul 2017 9:05AM $0.098 $1.270 risen by 1,195.92%
$39 Change in substantial shareholder 17 May 2017 9:32AM $0.115 $1.270 risen by 1,004.35%
$39 Cleansing Notice & Appendix 3B 12 May 2017 4:13PM $0.120 $1.270 risen by 958.33%
$39 Second subject recruited at Monash Health Melbourne 11 May 2017 9:29AM n/a $1.270 n/a
$39 Dr Roger Aston, Non-Executive Director 4 May 2017 10:16AM $0.115 $1.270 risen by 1,004.35%
$39 Appointment of Dr Chris Roberts AO as Chairman 3 May 2017 9:12AM $0.120 $1.270 risen by 958.33%
$39 Appendix 4C and Quarterly update 27 Apr 2017 9:38AM $0.130 $1.270 risen by 876.92%
$39 First OncoSil Device Implantation procedure completed 26 Apr 2017 9:38AM $0.125 $1.270 risen by 916%
$39 Specialised Therapeutics Australia supporting OncoSil study 20 Apr 2017 9:30AM $0.125 $1.270 risen by 916%
$39 US IRB Approval, MD Anderson Cancer Centre 19 Apr 2017 9:11AM $0.125 $1.270 risen by 916%
$39 Loan Share Vesting Conditions Met 10 Apr 2017 4:04PM $0.125 $1.270 risen by 916%
$39 Notice of change of substantial holder 10 Apr 2017 4:04PM $0.125 $1.270 risen by 916%
$39 UK Central Ethics Approval 4 Apr 2017 9:42AM $0.094 $1.270 risen by 1,251.06%
$39 First subject recruited 28 Mar 2017 9:32AM $0.079 $1.270 risen by 1,507.59%
$39 Appendix 3X - Initial Directors Interest Notice 28 Feb 2017 5:00PM $0.086 $1.270 risen by 1,376.74%
$39 Dr Martin Cross appointed Non-Executive Director 28 Feb 2017 9:35AM $0.086 $1.270 risen by 1,376.74%
$39 Appendix 4D & Half Year Accounts 23 Feb 2017 9:56AM $0.087 $1.270 risen by 1,359.77%
$39 MHRA Approval to commence study in UK 13 Feb 2017 9:53AM $0.093 $1.270 risen by 1,265.59%
$39 CE Mark Update 8 Feb 2017 5:14PM $0.098 $1.270 risen by 1,195.92%
$39 Ethics Approval for OncoPac Clinical Study 2 Feb 2017 9:18AM $0.099 $1.270 risen by 1,182.83%
$39 Appendix 4C - Quarterly Cash Flow 27 Jan 2017 9:28AM $0.089 $1.270 risen by 1,326.97%
$39 Amended Escrow Date 20 Jan 2017 3:47PM $0.096 $1.270 risen by 1,222.92%

651 - 675 of 791 results

Page 27 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.